Ticker Appearances
Daily Technical Strategy
Tech Hardware favored over Software; Meanwhile Pharma/Biotech slides further
NEAR-TERM AND INTERMEDIATE-TERM TECHNICAL TRENDS REMAIN BULLISH FOR US EQUITIES, AND WEDNESDAY’S BOUNCE MADE SUFFICIENT PROGRESS TO HELP ESTABLISH A NEW SHORT-TERM UPTREND, WHICH ARGUABLY...
This report is accessible to Fundstrat Pro & Fundstrat Macro memberships.
You have viewed the limit of 2 Macro reports for free this month.
To continue reading our research please sign up below.
Already have an account? Sign In unknown
Visitor: unknown Array ( [current_usage] => 2 [current_usage_crypto] => 2 [max_usage] => 2 [max_usage_crypto] => 2 )
Daily Technical Strategy
Tech remains quite strong vs. SPX despite some mixed results
QQQ, DJIA AND SPX ARE RIGHT AT OCTOBER LOWS, AND SHOULD ATTEMPT TO MAKE A STAND THIS WEEK. HOWEVER, THIS LIKELY DOES DEPEND ON STELLAR...
This report is accessible to Fundstrat Pro & Fundstrat Macro memberships.
You have viewed the limit of 2 Macro reports for free this month.
To continue reading our research please sign up below.
Already have an account? Sign In unknown
Visitor: unknown Array ( [current_usage] => 2 [current_usage_crypto] => 2 [max_usage] => 2 [max_usage_crypto] => 2 )
First Word
COVID-19 UPDATE: USA on cusp of "40%" level that presaged 53% plunge in Israel cases... Updating Granny Shots, +9, -13, net -4 stocks = 28 grREVISED Granny Shot ideas
So 3 of the major items over the weekend were all positive and support the US moving towards a full re-opening by mid-June. Of these...
This report is accessible to Fundstrat Pro & Fundstrat Macro memberships.
You have viewed the limit of 2 Macro reports for free this month.
To continue reading our research please sign up below.
Already have an account? Sign In unknown
Visitor: unknown Array ( [current_usage] => 2 [current_usage_crypto] => 2 [max_usage] => 2 [max_usage_crypto] => 2 )
Daily Technical Strategy
Tech Hardware favored over Software; Meanwhile Pharma/Biotech slides further
NEAR-TERM AND INTERMEDIATE-TERM TECHNICAL TRENDS REMAIN BULLISH FOR US EQUITIES, AND WEDNESDAY’S BOUNCE MADE SUFFICIENT PROGRESS TO HELP ESTABLISH A NEW SHORT-TERM UPTREND, WHICH ARGUABLY...
This report is accessible to Fundstrat Pro & Fundstrat Macro memberships.
You have viewed the limit of 2 Macro reports for free this month.
To continue reading our research please sign up below.
Already have an account? Sign In unknown
Visitor: unknown Array ( [current_usage] => 2 [current_usage_crypto] => 2 [max_usage] => 2 [max_usage_crypto] => 2 )
Daily Technical Strategy
Tech remains quite strong vs. SPX despite some mixed results
QQQ, DJIA AND SPX ARE RIGHT AT OCTOBER LOWS, AND SHOULD ATTEMPT TO MAKE A STAND THIS WEEK. HOWEVER, THIS LIKELY DOES DEPEND ON STELLAR...
This report is accessible to Fundstrat Pro & Fundstrat Macro memberships.
You have viewed the limit of 2 Macro reports for free this month.
To continue reading our research please sign up below.
Already have an account? Sign In unknown
Visitor: unknown Array ( [current_usage] => 2 [current_usage_crypto] => 2 [max_usage] => 2 [max_usage_crypto] => 2 )
First Word
COVID-19 UPDATE: USA on cusp of "40%" level that presaged 53% plunge in Israel cases... Updating Granny Shots, +9, -13, net -4 stocks = 28 grREVISED Granny Shot ideas
So 3 of the major items over the weekend were all positive and support the US moving towards a full re-opening by mid-June. Of these...
This report is accessible to Fundstrat Pro & Fundstrat Macro memberships.
You have viewed the limit of 2 Macro reports for free this month.
To continue reading our research please sign up below.
Already have an account? Sign In unknown
Visitor: unknown Array ( [current_usage] => 2 [current_usage_crypto] => 2 [max_usage] => 2 [max_usage_crypto] => 2 )
Daily Technical Strategy
Tech Hardware favored over Software; Meanwhile Pharma/Biotech slides further
NEAR-TERM AND INTERMEDIATE-TERM TECHNICAL TRENDS REMAIN BULLISH FOR US EQUITIES, AND WEDNESDAY’S BOUNCE MADE SUFFICIENT PROGRESS TO HELP ESTABLISH A NEW SHORT-TERM UPTREND, WHICH ARGUABLY...
This report is accessible to Fundstrat Pro & Fundstrat Macro memberships.
You have viewed the limit of 2 Macro reports for free this month.
To continue reading our research please sign up below.
Already have an account? Sign In unknown
Visitor: unknown Array ( [current_usage] => 2 [current_usage_crypto] => 2 [max_usage] => 2 [max_usage_crypto] => 2 )
